Bolt-on acquisitions and mergers between Chinese biotechs and major drug makers had not yet come into fashion over the past year, although the two groups continued to pursue tie-ups in their efforts to continue with innovative drug development despite a sustained downward market.
Fewer Biotech-Pharma M&As But Tie-ups Indicate New China Trends
The past year witnessed only one major acquisition of a Chinese biotech by a major pharma company. However, some established firms such as Hansoh have set a new course for collaboration with much smaller peers by in-licensing preclinical assets.
